Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bldg. 35, 35 Convent Drive, Bethesda, MD 20892-3707, U.S.A.
Biochem Soc Trans. 2019 Apr 30;47(2):651-661. doi: 10.1042/BST20180462. Epub 2019 Mar 5.
The past two decades in research has revealed the importance of leucine-rich repeat kinase 2 (LRRK2) in both monogenic and sporadic forms of Parkinson's disease (PD). In families, mutations in LRRK2 can cause PD with age-dependent but variable penetrance and genome-wide association studies have found variants of the gene that are risk factors for sporadic PD. Functional studies have suggested that the common mechanism that links all disease-associated variants is that they increase LRRK2 kinase activity, albeit in different ways. Here, we will discuss the roles of LRRK2 in areas of inflammation and vesicular trafficking in the context of monogenic and sporadic PD. We will also provide a hypothetical model that links inflammation and vesicular trafficking together in an effort to outline how these pathways might interact and eventually lead to neuronal cell death. We will also highlight the translational potential of LRRK2-specific kinase inhibitors for the treatment of PD.
过去二十年的研究揭示了富含亮氨酸重复激酶 2(LRRK2)在单基因和散发性帕金森病(PD)中的重要性。在家族中,LRRK2 突变可导致 PD,其具有年龄依赖性但可变的外显率,全基因组关联研究发现了该基因的变体,这些变体是散发性 PD 的风险因素。功能研究表明,将所有与疾病相关的变异联系在一起的共同机制是它们增加了 LRRK2 激酶活性,尽管方式不同。在这里,我们将讨论 LRRK2 在单基因和散发性 PD 中的炎症和囊泡运输领域的作用。我们还将提供一个假设模型,将炎症和囊泡运输联系在一起,努力概述这些途径如何相互作用并最终导致神经元细胞死亡。我们还将强调 LRRK2 特异性激酶抑制剂在 PD 治疗中的转化潜力。